Plus: J&J’s Duato: GLP-1 space ‘too crowded’ to enter, Pfizer leaving BIO and updates from Merck KGaA, Pharvaris, Novartis, Arvinas, Seagen, EyePoint and CatalYm
Mark Shearman will join Editas Medicine Inc. (NASDAQ:EDIT) in June as EVP and CSO. Shearman currently serves as CSO of Applied Genetic Technologies Corp. (NASDAQ:AGTC). Kyowa Kirin Co. Ltd.
Flagship-backed cloud computing-based drug discovery and development company Valo Health LLC named Nish Lathia chief product officer. The 18-year veteran of Amazon.com Inc. (NASDAQ:AMZN) held a